Miller Kovoor TA, Kim AS, et al. 2004. Evaluation of the corneal effects of topical ophthalmic ﬂuoroquinolones using in vivo confocal microscopy. Eye Contact Lens, 30:90–4. Kowalski RP, Dhaliwal DK, et al. 2003. Gatiﬂoxacin and moxiﬂoxacin:an in vitro susceptibility comparison to levoﬂoxacin, ciproﬂoxacin, and oﬂoxa- cin using bacterial keratitis isolates. Am J Ophthalmol, 136:500–5. Kowalski RP, Yates KA, et al. 2005. An ophthalmologist’s guide to under- standing antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology, 112:1987. Krasemann C, Meyer J, et al. 2001. Evaluation of the clinical microbiology proﬁle of moxiﬂoxacin. Clin Infect Dis, 32(Suppl 1):S51–63. Lee SB, Oliver KM, et al. 2005. Fourth-generation ﬂuoroquinolones in the treatment of mycobacterial infectious keratitis after laser-assisted in situ keratomileusis surgery. Can J Ophthalmol, 40:750–3. Ly LT, Cavanagh HD, et al. 2006. Confocal assessment of the effects of fourth-generation ﬂuoroquinolones on the cornea. Eye Contact Lens, 32:161–5. Mah FS. 2004. Fourth-generation ﬂuoroquinolones: new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol, 15:316–20. Mallari PL, McCarty DJ, et al. 2001. Increased incidence of corneal perfora- tion after topical ﬂuoroquinolone treatment for microbial keratitis. Am J Ophthalmol, 131:131–3. Marangon FB, Miller D, et al. 2004. Ciproﬂoxacin and levoﬂoxacin resis- tance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol, 137:453–8. Mather R, Karenchak LM, et al. 2002. Fourth generation ﬂuoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol, 133:463–6. Mather R, Stewart JM, et al. 2004. The effect of cataract surgery on ocular levels of topical moxiﬂoxacin. Am J Ophthalmol, 138:554–9. Matieli LC, De Freitas D, et al. 2006. Mycobacterium abscessus endo- phthalmitis: treatment dilemma and review of the literature. Retina, 26:826–9. Matsumoto S, Way W, et al. 2006. Comparative toxicity of ﬂuoroquinolone antibiotics on corneal cells in vitro. Cornea, 25(9 Suppl 2):S1–7. McCulley JP, Caudle D, et al. 2006. Fourth-generation ﬂuoroquinolone penetration into the aqueous humor in humans. Ophthalmology, 113:955–9. McDermott M, Wheater M. 2006. In vitro comparison of the effects of clinically available ophthalmic solutions of gatiﬂoxacin 0.3% and moxiﬂoxacin 0.5% on human corneal and conjunctival epithelial cell adhesion and migration and on collagen type IV protein expression. Cornea, 25(9 Suppl 2):S25–S30. McGee DH, Holt WF, et al. 2005. Safety of moxiﬂoxacin as shown in animal and in vitro studies. Surv Ophthalmol, 50(Suppl 1):S46–54. Metzler K, Hansen GM, et al. 2004. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 ﬂuoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents, 24:161–7. Miller D, Alfonso EC. 2004. Comparative in vitro activity of levoﬂoxacin, oﬂoxacin, and ciproﬂoxacin against ocular streptococcal isolates. Cornea, 23:289–93. Miller D, Flynn PM, et al. 2006. In vitro ﬂuoroquinolone resistance in staph- ylococcal endophthalmitis isolates. Arch Ophthalmol, 124:479–83. Miller JJ, Scott IU, et al. 2005. Acute-onset endophthalmitis after cataract surgery (2000–2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol, 139:983–7. Mino de Kaspar H, Koss MJ, et al. 2005. Antibiotic susceptibility of preoperative normal conjunctival bacteria. Am J Ophthalmol, 139:730–3. Moshirfar M, Meyer JJ, et al. 2007. Fourth-generation ﬂuoroquinolone- resistant mycobacterial keratitis after laser in situ keratomileusis. J Cataract Refract Surg, 33:1978–81. Moshirfar M, Mirzaian G, et al. 2006. Fourth-generation ﬂuoroquinolone- resistant bacterial keratitis after refractive surgery. J Cataract Refract Surg, 32:515–8. 90 Munir WM, Rosenfeld SI, et al. 2007. Clinical response of contact lens- associated fungal keratitis to topical ﬂuoroquinolone therapy. Cornea, 26:621–4. Nielsen JS, Blatt S, et al. 2004. Clinicopathologic case report: scleral buckle associated nontuberculous mycobacterial scleritis. Semin Ophthalmol, 19(3–4):101–4. O’Brien TP. 2006. Evidence-based review of moxiﬂoxacin. Int Ophthalmol Clin, 46:61–72. Oliphant CM, Green GM. 2002. Quinolones: a comprehensive review. Am Fam Physician, 65:455–64. Oliveira AD, D’Azevedo PA, et al. 2007. In vitro activity of ﬂuoroquino- lones against ocular bacterial isolates in Sao Paulo, Brazil. Cornea, 26:194–8. Ong-Tone L. 2007. Aqueous humor penetration of gatiﬂoxacin and moxi- ﬂoxacin eyedrops given by different methods before cataract surgery. J Cataract Refract Surg, 33:59–62. Ozdek SC, Miller D, et al. 2006. In vitro antifungal activity of the fourth generation ﬂuoroquinolones against Candida isolates from human ocular infections. Ocul Immunol Inﬂamm, 14:347–51. Peterson LR. 2001. Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clin Infect Dis, 33(Suppl 3):S180–6. Pong A, Thomson KS, et al. 1999. Activity of moxiﬂoxacin against patho- gens with decreased susceptibility to ciproﬂoxacin. J Antimicrob Chemother, 44:621–7. Robertson SM, Curtis MA, et al. 2005. Ocular pharmacokinetics of moxi- ﬂoxacin after topical treatment of animals and humans. Surv Ophthal- mol, 50(Suppl 1):S32–45. Robicsek A, Jacoby GA, et al. 2006. The worldwide emergence of plasmid- mediated quinolone resistance. Lancet Infect Dis, 6:629–40. Robicsek A, Strahilevitz J, et al. 2006. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med, 12:83–8. Saravolatz LD, Leggett J. 2003. Gatiﬂoxacin, gemiﬂoxacin, and moxiﬂoxa- cin:the role of 3 newer ﬂuoroquinolones. Clin Infect Dis, 37:1210–5. Schlech BA, Alfonso E. 2005. Overview of the potency of moxiﬂoxacin ophthalmic solution 0.5% (VIGAMOX). Surv Ophthalmol, 50(Suppl 1):S7–15. Sharma S, KDY, et al. 1999. Trends in antibiotic resistance of corneal pathogens: Part I. An Analysis of commonly used antibiotics. Indian J Ophthalmol, 47:95–100. Smith A, Pennefather PM, et al. 2001. Fluoroquinolones: place in ocular therapy. Drugs, 61:747–61. Smith HJ, Walters M, et al. 2004. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efﬂux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother, 48:3954–8. Solomon R, Donnenfeld ED, et al. 2003. Bilateral methicillin-resistant staphy- lococcus aureus keratitis in a medical resident following an uneventful bilateral photorefractive keratectomy. Eye Contact Lens, 29:187–9. Solomon R, Donnenfeld ED, et al. 2007. Methicillin-resistant Staphylo- coccus aureus infectious keratitis following refractive surgery. Am J Ophthalmol, 143:629–34. Solomon R, Donnenfeld ED, et al. 2005. Penetration of topically applied gatiﬂoxacin 0.3%, moxiﬂoxacin 0.5%, and ciproﬂoxacin 0.3% into the aqueous humor. Ophthalmology, 112:466–9. Spencer TS, Teske MP, et al. 2005. Postcataract endophthalmitis caused by Mycobacterium goodii. J Cataract Refract Surg, 31:1252–3. Stern ME, Gao J, et al. 2006. Effects of fourth-generation ﬂuoroquinolones on the ocular surface, epithelium, and wound healing. Cornea, 25(9 Suppl 2):S12–S24. Stroman DW, Dajcs JJ, et al. 2005. In vitro and in vivo potency of moxi- ﬂoxacin and moxiﬂoxacin ophthalmic solution 0.5%, a new topical ﬂuoroquinolone. Surv Ophthalmol, 50(Suppl 1):S16–31. Takei M, Fukuda H, et al. 2001. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother, 45:3544–7. Clinical Ophthalmology 2008:2(1)